MBRX (Moleculin Biotech) Other Operating Expense: $0.07 Mil (TTM As of Mar. 2026)


MBRX Moleculin Biotech Inc MBRX
30 GF Score
Price $2.23
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech Other Operating Expense?

Moleculin Biotech MBRX -2.00% 30 Other Operating Expense is $0.07 Mil as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Moleculin Biotech's Other Operating Expense for the three months ended in Mar. 2026 was $0.01 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.07 Mil.

Moleculin Biotech's quarterly Other Operating Expense declined from Sep. 2025 ($0.02 Mil) to Dec. 2025 ($0.01 Mil) and declined from Dec. 2025 ($0.01 Mil) to Mar. 2026 ($0.01 Mil).

Moleculin Biotech's annual Other Operating Expense declined from Dec. 2023 ($0.13 Mil) to Dec. 2024 ($0.13 Mil) and declined from Dec. 2024 ($0.13 Mil) to Dec. 2025 ($0.09 Mil).

Moleculin Biotech Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Other Operating Expense Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.13 0.13 0.13 0.09

Moleculin Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.02 0.01 0.01
MBRX
30GF Score
Moleculin Biotech Inc MBRX
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $0.07 Mil mean?
Moleculin Biotech (MBRX) has a Other Operating Expense of $0.07 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Moleculin Biotech and its competitors.
Is Moleculin Biotech's Other Operating Expense too high?
Moleculin Biotech's current Other Operating Expense is $0.07 Mil. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Other Operating Expense compare to JAGX and BCDA?
Moleculin Biotech's Other Operating Expense of $0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current Other Operating Expense is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current Other Operating Expense of $0.07 Mil. The current Other Operating Expense is $0.07 Mil. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Other Operating Expense is $0.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Other Exchanges 0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for MBRX

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.23
Price